VRML - バ―ミリオン (Vermillion Inc.) バ―ミリオン

 VRMLのチャート


 VRMLの企業情報

symbol VRML
会社名 Vermillion Inc (バ―ミリオン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Vermillion Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to in addition to a physician's clinical assessment of a woman with a pelvic mass identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2 500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.   バ―ミリオンは、米国の診断検査プロバイダ―。主に婦人科癌および関連疾患の患者向けの医療検査の発見、開発、商品化に従事する。主要製品OVA1は、ソフトウェアアルゴリズム及び血液検査を統合卵巣癌試験システムで、悪性卵巣腫瘍の識別検査。本社はテキサス州オ―スティン。   Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
本社所在地 12117 Bee Caves Road Building Three Suite 100 Austin TX 78738 USA
代表者氏名 James T. LaFrance James T. LaFrance
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 512-519-0400
設立年月日 34304
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 40人
url www.vermillion.com
nasdaq_url https://www.nasdaq.com/symbol/vrml
adr_tso
EBITDA EBITDA(百万ドル) -10.55000
終値(lastsale) 0.64
時価総額(marketcap) 48175520.64
時価総額 時価総額(百万ドル) 35.76280
売上高 売上高(百万ドル) 2.85400
企業価値(EV) 企業価値(EV)(百万ドル) 23.20180
当期純利益 当期純利益(百万ドル) -12.30500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Vermillion Inc. revenues decreased 16% to $1.4M. Net loss increased 17% to $5.9M. Revenues reflect Product decrease of 19% to $1.2M. Higher net loss reflects Sales and Marketing - other increase of 32% to $2.6M (expense) General and administrative increase of 3% to $2.2M (expense) Other income (expense) net increase of 56% to $14K (expense).

 VRMLのテクニカル分析


 VRMLのニュース

   Vermillion : Set to Join Russell 3000 Index | MarketScreener  2020/06/11 07:38:15 MarketScreener
Vermillion Set to Join Russell 3000® Index AUSTIN, Texas - June 9, 2020 - Vermillion, Inc. , a bioanalytical-based women's health company focused on… | June 11, 2020
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   Vermillion : Reports First Quarter 2020 Financial Results | MarketScreener  2020/06/02 13:26:11 MarketScreener
Vermillion Reports First Quarter 2020 Financial Results Conference Call scheduled for today, May 14th at 4:30 p.m. ET AUSTIN, Texas - May… | June 2, 2020
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women  2019/12/17 13:00:00 Business Wire
AUSTIN, Texas & PHILADELPHIA--(BUSINESS WIRE)-- #OVA1--Vermillion, Inc. and Einstein Medical Center announced first patient enrolled in study for detection of ovarian cancer risk in African American women.
   GenomeSmartTM and ASPiRA LABS®, a Vermillion Company, Launch Pilot Program to Improve Access to Genetic Testing  2019/12/03 11:00:00 Business Wire
LOS ALTOS, Calif. & AUSTIN, Texas--(BUSINESS WIRE)-- #GeneticTesting--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, today announced a pilot program with ASPiRA LABS®, a Vermillion company (Nasdaq: VRML), where GenomeBrainTM will be offered to a select group of providers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to th
   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:48:08 Seeking Alpha
Vermillion, Inc. (NASDAQ:VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri – President and Chief Executive Of
   Vermillion Reports First Quarter 2020 Financial Results  2020/05/14 20:01:00 GlobeNewswire
Conference Call scheduled for today, May 14th at 4:30 p.m. ET
   Vermillion Reports Fourth Quarter 2019 Financial Results | MarketScreener  2020/03/26 20:02:03 MarketScreener
Conference Call scheduled for today, March 26th at 4:30 p.m. ET AUSTIN, Texas, March 26, 2020 -- Vermillion, Inc. , a bio-analytical based women’s health company focused on… | March 26, 2020
   Vermillion, Inc. and Einstein Medical Center Philadelphia Announce the First Patient Enrolled in Prospective National Clinical Study of Ovarian Cancer Risk Detection Methods in African American Women  2019/12/17 13:00:00 Business Wire
AUSTIN, Texas & PHILADELPHIA--(BUSINESS WIRE)-- #OVA1--Vermillion, Inc. and Einstein Medical Center announced first patient enrolled in study for detection of ovarian cancer risk in African American women.
   GenomeSmartTM and ASPiRA LABS®, a Vermillion Company, Launch Pilot Program to Improve Access to Genetic Testing  2019/12/03 11:00:00 Business Wire
LOS ALTOS, Calif. & AUSTIN, Texas--(BUSINESS WIRE)-- #GeneticTesting--GenomeSmart, a Silicon Valley-based company delivering the first and only AI-powered genetic risk assessment and test recommendation platform to improve access to genetic testing, today announced a pilot program with ASPiRA LABS®, a Vermillion company (Nasdaq: VRML), where GenomeBrainTM will be offered to a select group of providers to improve identification of patients who are at risk for hereditary cancer or passing hereditary diseases to th
   Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:48:08 Seeking Alpha
Vermillion, Inc. (NASDAQ:VRML) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Valerie Palmieri – President and Chief Executive Of

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バ―ミリオン VRML Vermillion Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)